Navigation Links
Common drugs initiate a molecular pas de quatre at the surface of the cell membrane
Date:7/26/2011

Brussels, 25 July 2011 - G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. They act as molecular switches that transduce extracellular signals by activating heterotrimeric G proteins (G proteins) located at the inside of the cell. Changes in shape of these proteins determine essential processes, including whether an eye detects light, a virus invades a cell or a drug slows a racing heart. GPCRs sit in the membranes of cells throughout the body. They pick up signals from outside the body such as odors, flavors or light and signals from within the body, such as neurotransmitters or hormones. Once those signals are transmitted to the inside of the cell, they activate intracellular G proteins, triggering a variety of biochemical pathways. Despite their importance in biology and medicine, the way G protein-coupled receptors couple the detection of a signals from the outside world to the activation of the G-protein at the inside of the cell has remained largely unknown an important obstacle to understanding their function.

In an article in Nature, scientists from Stanford University, University of Wisconsin and VIB-Vrije Universiteit Brussel now reveal the complete three-dimensional atomic structure of an activated GPCR the beta-2 adrenergic receptor (beta-2AR) in a complex with its G protein. This is an important step towards the understanding of how the receptors actually work.

Beta-2 AR is activated by the hormones adrenaline and noradrenaline. Activation of the receptor lies at the basis of the body's fight-or-flight response by speeding up the heart, increasing blood pressure and opening airways. As a result, it is a key target for anti-asthma and blood pressure medications.

Adrenaline binds from the outside of the cell to the adrenergic receptor that is embedded in the cellular membrane, causing the heterotrimeric G protein (Gs) to fall apart in two pieces (G-alpha-S and G-beta-gamma). One piece (G-alpha-S) transmits the adrenaline signal to an effector enzyme; the other piece (G-beta-gamma) transmits the signal to an effector ion channel.

Although the receptor beta-2AR been discovered 20 years ago, the exact mechanism of its function remained unknown, impeding improvements of the drugs that act on this receptor. To explain the function of this receptor, it was important to catch the signaling complex in the act, a dance in two parts featuring four key players: the hormone (adrenaline or noradrenaline), the receptor and the G protein that is built from G-alpha-S and G beta-gamma.

Now, 20 year later, this is exactly what the researchers Stanford University, University of Wisconsin and VIB-Vrije Universiteit Brussel have accomplished. They produced two key freeze-frame pictures of this dance. In January 2011, they produced the first images of an active receptor, coupled to a drug-like molecule that acts like the hormone. In a follow-up article in Nature, they now present the poignant moment in the ballet the four-partner embrace that includes the hormone, the receptor, G-alpha-S and G-beta-gamma. These findings provide the very first three dimensional insights in transmembrane signaling trough GPCRs, a molecular process that is considered to be one of the most fascinating problems in biology. The discovery is important because the interactions between the GPCR and G-alpha-beta-gamma are pharmacologically relevant and unlock the secrets of functional selectivity, the ability of different drugs to coax distinct downstream effects from a single kind of receptor.

Obtaining a 3D image of the Hormone:GPCR:G-alpha-beta-gamma complex proved to be very complicated. The large and membrane embedded complex is unstable, difficult to prepare and the components are difficult to express and purify. Jan Steyaert and Els Pardon in Brussels produced a Xaperone, that binds simultaneously on G-alpha-S and G-beta-gamma and holds these proteins together in the complex. The structure of this stabilized complex was determined using X-ray crystallography techniques. The Advanced Photon Source beamline 23 ID-B at the Aragon Synchrotron, one of the most powerfull X-ray sources worldwide was used as a molecular camera.


'/>"/>

Contact: Joris Gansemans
info@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Study provides insight on a common heart rhythm disorder
2. Researchers identify Achilles heel of common childhood tumor
3. First comprehensive genomic study of common cold reveals new treatment targets
4. GUMC researchers hone in on new strategy to treat common infection
5. Hairspray is linked to common genital birth defect, says study
6. Common food additive found to increase risk and speed spread of lung cancer
7. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
8. Scientists uncover evolutionary keys to common birth disorders
9. Common soil mineral degrades the nearly indestructible prion
10. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
11. New vaccine developed for preventing uncommon cold virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... BERG, a biopharmaceutical company uncovering health ... announced the appointment of Jason Haddock ... Haddock brings to BERG over 20 years of ... senior financial functions at pharmaceutical companies, as well ... Niven R. Narain , BERG,s ...
(Date:2/8/2016)... Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... ten finalists for clean technology companies in the TSX Venture ... 10 companies listed on the TSX Venture Exchange, in each ... clean technology & life sciences, diversified industries and ... given to return on investment, market cap growth, trading volume ...
(Date:2/8/2016)... 2016  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced that it has entered into ... Technology Growth Capital, Inc. and Hercules Technology III, ... --> --> ... financing under the loan and security agreement.  The ...
(Date:2/8/2016)... -- Novan, Inc. today announced that Director Robert A. Ingram ... Novan. In addition, Robert Keegan has been appointed to ... . --> North Carolina . ... total of $32.8 million of net proceeds in a private Mezzanine ... throughout the Research Triangle area of North Carolina ...
Breaking Biology Technology: